Google DeepMind, Meta, and AI drug-discovery startup Isomorphic Labs are jointly funding a $300 million initiative to model cells computationally for disease research.
Google DeepMind, Meta, and Isomorphic Labs are putting $300 million into building a 'virtual cell' — a computational model researchers could use to simulate disease mechanisms and accelerate drug discovery. The initiative pairs Meta's AI research muscle with Isomorphic Labs' pharma-focused modeling work, under Google DeepMind's broader life sciences push.
This is one of the largest cross-company AI-for-biology commitments disclosed this year, and it comes as competing efforts in computational biology race to demonstrate real drug pipeline wins rather than research papers.
Three major AI players co-funding a single biology infrastructure project is a tell: the most defensible AI value isn't in consumer chatbots, it's in domain-specific models that compress years of wet-lab research into simulation. Pharma and biotech leaders should watch this as a signal of where platform-level AI investment is heading next.
The daily signal, curated. Get it in your inbox.
Subscribe on LinkedIn →